trials: no further need at the moment, page-28

trent26

You write: "With Bio A sales increasing exponentially it may be the product that will be the cash cow in Australia and other western countries without the need for Bio R."

Are the sales increasing exponentially?

I am looking at SLA's June 2008 Quarterly. Receipts from customers for that quarter are $31,000.

Assuming that all those receipts are for Bio A, and assuming that SLA receives 2/3rds of the retail price from wholesalers, then SLA sold some 1,000 packets of Bio A in the June quarter. Bio A looks more like being a cash minnow than a cash cow.

Receipts for the whole financial year were $146,000. Since the June quarter was below average I don't see signs of an exponential increase in sales of Bio A.

Or have I missed something?